Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
Korean Circulation Journal
;
: 183-191, 2019.
Article
in English
| WPRIM
| ID: wpr-738765
ABSTRACT
BACKGROUND AND OBJECTIVES:
We investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens.METHODS:
Between March 2010 and February 2017, 16 hospitals participated in this study. A total of 102 (32.3±19.9 months, 72 males) who received infliximab at any time after first IVIG treatment failure were enrolled. Data were retrospectively collected using a questionnaire.RESULTS:
Subjects were divided into two groups according to the timing of infliximab administration. Early treatment (group 1) had shorter fever duration (10.5±4.4 days) until infliximab infusion than that in late treatment (group 2) (16.4±4.5 days; p 5). Overall response rate to infliximab was 89/102 (87.3%) and the incidence of significant CAA was lower in group 1 than in group 2 (1/42 [2.4%] vs. 17/60 [28.3%], p < 0.001).CONCLUSIONS:
This study suggests that the early administration of infliximab may reduce the incidence of significant CAA in patients with IVIG-resistant KD. However, further prospective randomized studies with larger sample sizes are required.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Immunoglobulins
/
Incidence
/
Prospective Studies
/
Retrospective Studies
/
Immunoglobulins, Intravenous
/
Treatment Failure
/
Sample Size
/
Coronary Vessels
/
Fever
/
Infliximab
Type of study:
Incidence study
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Korean Circulation Journal
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS